Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Mirion Technologies Inc. Class A

Mirriad Advertising ( ($GB:MIRI) ) has issued an announcement. Mirriad Advertising has failed to secure the urgent funding needed to continue as a ...

Mirriad moves core subsidiaries into insolvency as funding bid fails

Mirrabooka Investments Ltd ( ($AU:MIR) ) just unveiled an update. Mirrabooka Investments Limited has reported an estimated pre-tax net tangible ass...

Mirrabooka posts updated pre-tax NTA backing for April

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pha...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), GeneDx Holdings (WGS) and Agios Pharma (AGIO)

Mirrabooka Investments Ltd ( ($AU:MIR) ) just unveiled an update. Mirrabooka Investments has reported an estimated pre-tax net tangible asset backi...

Mirrabooka Shares Trade Below Updated Asset Backing

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Boeing (BA) and Mirion Technologies (MIR) with...

Analysts Offer Insights on Industrial Goods Companies: Boeing (BA) and Mirion Technologies (MIR)

The latest announcement is out from Mirion Technologies ( ($MIR) ). On April 9, 2026, Mirion Technologies’ board approved a one-time grant of 2.5 m...

Mirion Grants CEO Large Performance-Based Stock Option Award

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an announcement. Mirrabooka Investments Limited has reported an estimated pre-tax net tangible ...

Mirrabooka posts estimated pre-tax NTA of $2.81 per share

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM...

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an update. Mirrabooka Investments reported a decline in its net tangible asset backing per shar...

Mirrabooka NTA Slips as Mid and Small-Cap Portfolio Holds Course

Medmira ( ($TSE:MIR) ) just unveiled an update. MedMira reported second-quarter fiscal 2026 results marked by weaker revenue and a wider net loss, ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIR	$19.25	-2.33%	4.81M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIR	$19.25	-2.3%	4.81M
3
4
5
6

MIR

MIR

Get Mirion Technologies Inc. Class A Data in Excel

Get Mirion Technologies Inc. Class A Data in Excel